H.C. Wainwright analyst Douglas Tsao raised the firm’s price target on Arcutis Biotherapeutics (ARQT) to $34 from $30 and keeps a Buy rating on the shares. The firm views the company’s Q4 report as strong.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARQT:
- Arcutis: Strong Zoryve Outperformance, Upgraded 2026 Outlook, and Pipeline Momentum Support Buy Rating
- Arcutis Biotherapeutics files automatic mixed securities shelf
- Arcutis Biotherapeutics files to sell common stock for holders, no amount given
- Arcutis Biotherapeutics reports Q4 EPS 13c, consensus 9c
- Arcutis announces Max Homa joins ‘Free to Be Me’ campaign